A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2012
The primary objective of this study is to evaluate the efficacy of 3 subcutaneous doses of mavrilimumab compared with placebo in combination with methotrexate (MTX) in subjects with moderate-to-severe adult onset Rheumatoid Arthritis (RA).
Epistemonikos ID: 4f9f9dbed77840c897135f4bd62c5b1a0e003a3f
First added on: Mar 23, 2022